Drug Profile
LIM Pyr1
Alternative Names: LIM-Pyr1Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator CELLIPSE
- Class Antineoplastics
- Mechanism of Action LIM kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Leukaemia; Sarcoma
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Leukaemia in France
- 28 Aug 2020 No recent reports of development identified for research development in Sarcoma in France
- 27 Jul 2016 LIM Pyr1 is available for licensing as of 27 Jul 2016. http://cellipse.com/